Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
semaglutide + NNC0165-1875
- Development stage
- Phase 2
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
Semaglutide + NNC0165-1875 is a combination therapy under investigation for the treatment of obesity. Semaglutide is a glucagon-like peptide 1 receptor (GLP1R) agonist that reduces appetite, increases satiety, and lowers energy intake, leading to significant weight loss. It is approved for chronic weight management and type 2 diabetes. NNC0165-1875 (also known as PYY 1875) is a synthetic peptide that acts as an agonist of the neuropeptide Y receptor type 2 (NPY2R), which also plays a role in appetite regulation and satiety. The combination aims to enhance anti-obesity effects by targeting complementary pathways involved in hunger and fullness signaling. Both drugs are developed by Novo Nordisk[1][3][4][7].
- Other names
- PYY 1875PYY1875PYY-1875
02
Targets
GLP1R (GLP-1R)NPY2R (Neuropeptide Y receptor subtype 2)
Beyond the preview
Go deeper on semaglutide + NNC0165-1875.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on semaglutide + NNC0165-1875.